Cytokinetics posts MAPLE-HCM presentation on aficamten vs metoprolol in obstructive hypertrophic cardiomyopathy
CYTK•MAPLE-HCM presentation compares aficamten with metoprolol
Cytokinetics published a MAPLE-HCM analysis comparing aficamten versus metoprolol monotherapy in symptomatic obstructive hypertrophic cardiomyopathy.
The document reiterates the trial finding that aficamten outperformed metoprolol, with metoprolol showing no improvement in LVOT gradient.
The substudy tests whether prior beta-blocker use biased results by analyzing outcomes in patients with pretrial beta-blocker exposure versus none.
Participants received 24-week treatment with aficamten 5-20 mg daily or metoprolol 50-200 mg daily, with dose titration.
Pretrial groups included beta-blocker naive patients (52) versus beta-blocker users (123); a smaller SOC-naive subset totaled 22.
